Table 2 Main barriers to access to monoclonal antibodies targeting CGRP (MABs) according to responses from subjects who were not on MABs treatment (%). Total respondents N. 1684 (Question 3.2.3 b)
From: Who cares about migraine? Pathways and hurdles in the European region - access to care III
Reason | (%) |
|---|---|
Not mentioned by the doctors | 26 |
Not covered by the health system | 25 |
Not meeting eligibility criteria | 25 |
Not available in the home country | 10 |
Not known by doctors | 6 |
Not indicated | 8 |